The Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) tablets and capsules in combination with Venclexta (venetoclax) for adults with chronic lymphocytic leukemia (CLL) or ...

FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...

Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...

The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...

A cancer diagnosis hits like a thunderbolt, changing lives instantly and profoundly. Victor Gonzalez, senior director of patient programs and support services at The Lymphoma Research Foundation, ...

The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Relapsed/refractory CLL, I do kind of ...

Please provide your email address to receive an email when new articles are posted on . 61% of patients with heavily pretreated CLL responded to single-agent epcoritamab therapy. Researchers intend to ...

Both time-limited therapy and continuous therapy for chronic lymphocytic leukemia (CLL) have potential benefits and drawbacks. The best choice, a joint decision between clinician and patient, should ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center ...